Buchmann 2007.
| Methods | A cohort study of methylphenidate use for 10‐14 days | |
| Participants | Number of participants screened: not stated Number of participants included: 18 Number of participants followed up: 18 Number of withdrawals: not stated Diagnosis of ADHD: DSM‐IV (subtype: not stated) Age: mean: 11 years, SD: 1.91 years old IQ: > 85 Sex: 15 males, 3 females Methylphenidate‐naïve: 100% Ethnicity: not stated Country: Germany Comorbidity: no psychiatric comorbidity Comedication: none Sociodemographics: not stated Inclusion criteria:
Exclusion criteria:
|
|
| Interventions | Methylphenidate type: extended release methylphenidate Mean methylphenidate dosage: 0.78 (SD 0.26) mg/kg/day Administration schedule: once a day in the morning Duration of intervention: 10‐14 days Treatment compliance: children were inpatients for the duration of the study and received supervision when taking their medication |
|
| Outcomes | Data on adverse events were not systematically collected, so we could not use this data | |
| Notes | Sample calculation: not stated Any withdrawals due to adverse events: not stated Ethics approval: not stated Funding/vested interest: not stated Authors' affiliations: Department of Child and Adolescence Psychiatry and Neurology University of Rostock, Rostock, Germany. Key conclusions of the study authors: the methylphenidate group had the short interval cortical inhibition, intracortical facilitation and long interval cortical inhibition changes restored by the medication ‐ this was a very similar finding, compared to control group Exclusion of methylphenidate non‐responders/children who have previously experienced adverse events on methylphenidate: all participants were methylphenidate‐naïve Supplemental information regarding methods received through personal email correspondence with the authors in June 2014 (Buchmann 2014 [pers comm]) |
|